Τόμος 25 (2007) – Τεύχος 2+3 – Άρθρο 6 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 25 (2007) – Issue 2+3– Article 6 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Δήμητρα – Αλεξάνδρα Μηλιώνη¹, Μαρίνα Κλεοπάτρα Μποζίκη¹, Σοφία Γεωργιάδου¹, Αριστονίκη Βουλγαρίδου¹, Μαρία Μυρωνίδου-Τζουβελέκη²

¹Ιατρός, Μεταπτυχιακή Φοιτήτρια Π.Μ.Σ.Ι Ιατρική Ερευνητική Μεθοδολογία Αριστοτελείου Πανεπιστημίου Θεσσαλονίκης, Θεσσαλονίκη, Ελλάς²Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς

D.-A. Milioni¹, M.-K. Boziki¹, S. Geor­giadou¹, A. Voulgaridou¹ and M. Mironi­dou-Tzouveleki²

¹MD, postgraduate student, ²Laboratory of Phar­macology, Medical School, Aristotle Uni­versity, Thessaloniki, Greece

2. Gualtieri F., Manetti D., Romanelli M., Ghelardini C.: Design and study of piracetam-like nootropics, controver­sial members of the problematic class of cognition-en­hancing drugs. Curr. Pharmaceutical Design 8: 125-138 (2002)

3. Sharvan S.: Pyrrolidone derivatives. Lancet 358: 1885-1892 (2001)

4. McDaniel M., Maier S., Einstein G.: Brain-Specific nutrients: a memory cure? Nutrition 19: 957-975 (2003)

5. Orgogozo J.M.: Piracetam in the treatment of acute stroke. CNS Drugs 9 Suppl 1: 41-49 (1998)

6. Etcheberrigaray R., Alkon D.L.: Potassium channels and calcium release ± pathophysiological and diagnostic implications for Alzheimer’s disease. In: (Wasco W., Tanzi R.E., eds) Molecular Mechanisms of Dementia. Pp. 239-252, Humana Press, Totowa, NJ, 1997

7. Bukanova J., Solntseva E., Skrebitsky V.: Selective suppression of the slow-inactivating potassium currents by nootropics in molluscan neurons. Int. J. Neuropsycho­pharmacol. 5: 229-237 (2002)

8. Eckert G.P., Cairns N.J., Muller W.E.: Piracetam re­verses hippocampal membrane alterations in Alzheimer’s disease. J. Neural. Transm. 106: 757-61 (1999)

9. Mingeot-Leclercq M.P., Lins L., Bensliman M., Thomas A., Van Bambeke F., Peuvot J., Schanck A., Brasseur R.: Piracetam inhibits the lipid-destabilising effect of the amyloid peptide Abeta C-terminal fragment. Biochem. Biophys. Acta 1609: 28-38 (2003)

10. Gabryel B., Trzeciak HI., Pudelko A., Cieslik P.: Influ­ence of piracetam and oxiracetam on the content of high-energy phosphates and morphometry of astrocytes in vitro. Polish J. Pharmacol. 51: 485-495 (1999)

11. Israel L., Melac M., Milinkevitch D., Dubos G.: Drug therapy and memory training programs: a double-blind randomized trial of general practice patients with age-associated memory impairment. Int. Psychogeriatrics / IPA. 6: 155-170 (1994)

12. Tariska P., Paksy A.: Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia. Orvosi hetilap. 141: 1189-1193 (2000)

13. Dormehl I.C., Jordaan B., Oliver D.W., Croft S.: SPECT monitoring of improved cerebral blood flow dur­ing long-term treatment of elderly patients with nootropic drugs. Clin, Nuclear Med. 24: 29-34 (1999)

14. Tsolaki M., Pantazi T., Kazis A.: Efficacy of acetylcholi­nesterase inhibitors versus nootropics in Alz­heimer’s disease: a retrospective, longitudinal study. J. Int. Med. Res. 29: 28-36 (2001)

15. Flicker L., Grimley Evans J.: Piracetam for dementia or cognitive impairment. Cochrane Database of System­atic Reviews 2 (2000)

16. Waegemans T., Wilsher C.R., Danniau A., Ferris S.H., Kurz A., Winblad B.: Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement. Geri­atr. Cogn. Disord. 13: 217-24 (2002)

17. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., Galasko D., Jin S., Kaye J., Levey A., Pfeiffer E., Sano M., van Dyck C.H., Thal L.J., Alzheimer’s Disease Cooperative Study Group.: Vitamin E and donepezil for the treatment of mild cognitive im­pairment. N. Engl. J. Med. 352: 2379-2388 (2005)

18. Petersen R.C., Smith G.E., Ivnik R.J., Tangalos E.G., Schaid D.J., Thibodeau S.N., Kokmen E., Waring S.C., Kurland L.T.: Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals, J. Am. Med. Assoc. (JAMA) 273: 1274-1278 (1995)

19. Aggarwal N.T., Wilson R.S., Bienias J.L.: The apoli­poprotein E epsilon 4 allele and incident Alzheimer’s disease in person’s with mild cognitive impairment. Neu­rocase 11: 3-7 (2005)

20. Kluger A., Ferris S.H., Golomb J., Mittelman M.S., Reisberg B.: Neuropsychological prediction of decline to dementia in nondemented elderly. J. Geriat. Psych. Neu­rol. 12: 168-179 (1999)

21. Ritchie K.: Mild cognitive impairment: an epidemiol­ogical perspective. Dialog. Clin Neurosci. 6: 401-408 (2004)

22. Jelic V., Kipivelto M., Winblad B.: Clinical trials in mild cognitive impairment: lessons for the future. J. Neurol. Neurosurg. Psychiat. 77: 429-38 (2006)

23. Tian J.Z., Zhu A.H., Zhong J.: A follow-up study on a randomized, single-blind control of King’s Brain pills in treatment of memory disorder in elderly people with MCI in a Beijing community. Zhongguo Zhong Yao Za Zhi. 28: 987-991 (2003)

24. Dubois B., Albert M.L.: Amnestic MCI or prodromal Alzheimer’s disease? Lancet Neurol. 3: 246-248 (2004)

25. Gauthier S., Reisberg B., Zaudig M., Petersen R.C., Ritchie K., Broich K., Belleville S., Brodaty H., Bennett D., Chertkow H., Cummings J.L., de Leon M., Feldman H., Ganguli M., Hampel H., Scheltens P., Tierney M.C., Whitehouse P., Winblad B., International Psychogeriatric Association Expert Conference on mild cognitive impair­ment. Mild cognitive impairment. Lancet 367: 1262-1270 (2006)

26. De Deyn P.P., Reuck J.D., Deberdt W., Vlietinck R., Orgogozo J.Μ.: Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group. Stroke 28: 2347-2352 (1997)

27. Grotemeyer K.H., Evers S., Fischer M., Husstedt I.W.: Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. J. Neurologic. Sci. 181:  65-72 (2000)

28. Diener H.C., Cuhna L., Forbes C., Sivenius J., SmetsP., Lowenthal A.: European Stroke Prevention Study 2.Dipyramidole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurologic. Sci. 143: 1-13 (1996)

29. Ricci S., Celani M., Cantisani T.A, Righetti E.: Pi­racetam in acute stroke: a systematic review. J. Neurol.247: 263–266 (2000)

30. Ming A., Fritz V., Winterton R., Esser J., Hinton S.: Piracetam versus placebo in first, acute non-haemor­rhagic, carotid territory stroke: a double blind pilot study. Symposium Piracetam, Book of Abstracts 139-151, Ath­ens, 1990

31. Platt D., Horn J., Summa J., Shimtt-Rutt R., Kaunntz J., Kronert E.: On the efficacy of piracetam in geriatric patients with acute cerebral ischaemia: a clinical con­trolled double-blind study. Arch. Gerontol. Geriatr. 16: 149–164 (1993)

32. Enderby P., Broeckx J., Hospers W., Schildermans F., Deberdt W.: Effect of piracetam on recovery and reha­bilitation after stroke: a double-blind, placebo-controlled study. Clin. Neuropharmacol. 17: 320-31 (1994)

33. Bakheit A.M.O.: Drug treatment of post-stroke apha­sia, Expert Rev. Neurother. 4: 211-217 (2004)

34. Huber W., Willmes K., Poeck K., Van Vleymen B., Deberdt W.: Piracetam as an adjuvant to language ther­apy for aphasia: a randomized double-blind placebo-controlled pilot study. Arch. Phys. Med.  Rehabilit. 78: 245-50 (1997)

35. Berthier M.L.: Poststroke aphasia epidemiology, pathophysiology and treatment. Drugs Aging 22: 163-182 (2005)

36. Kessler J., Thiel A., Karbe H., Heiss W.D.: Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke 31: 2112-2116 (2000)

37. Szelies B., Mielke R., Kessler J., Heiss W.D.: Restitu­tion of alpha-topography by piracetam in post-stroke aphasia.  Int. J. Clin. Pharmacol. Ther. 39: 152-157 (2001)